Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ottmann

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Haematologica|January 2, 2015
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemiaFelicitas Thol, Michaela Scherr, Aylin Kirchner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialHubert Serve, Utz Krug, Ruth Wagner, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Cell|July 25, 2023
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapyGarry Dolton, Cristina Rius, Aaron Wall, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Haematologica|January 2, 2015
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemiaFelicitas Thol, Michaela Scherr, Aylin Kirchner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialHubert Serve, Utz Krug, Ruth Wagner, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Cell|July 25, 2023
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapyGarry Dolton, Cristina Rius, Aaron Wall, et al.
Pageof 6